Research To Practice | Oncology Videos

Featuring an interview with Dr Hope S Rugo, including the following topics: Pharmacologic features of antibody-drug conjugates (ADCs) and implications for their efficacy and toxicity in HR-positive breast cancer (0:00) Clinical and biological factors influencing the sequencing of approved ADCs for HR-positive and triple-negative metastatic breast cancer (4:03) Management of common toxicities with approved ADCs (10:48) Sacituzumab govitecan as first-line therapy for metastatic triple-negative breast cancer (18:17) Trastuzumab deruxtecan in combination with pertuzumab as first-line therapy for HER2-positive metastatic breast cancer (21:09) CME information and select publications

Featuring a slide presentation and related discussion from Dr Hope S Rugo, including the following topics: Current treatment landscape for and outcomes in HR-positive, HER2-negative metastatic breast cancer (mBC) (0:00) Trastuzumab deruxtecan for HER2-low and HER2-ultralow mBC (7:49) Sacituzumab govitecan for HR-positive, HER2-negative mBC (20:44) Datopotamab deruxtecan for HR-positive, HER2-negative mBC (27:29) Novel antibody-drug conjugates under investigation for HR-positive mBC (33:19) CME information and select publications

Featuring perspectives from Dr Rashmi Chugh and Dr Mrinal Gounder, including the following topics: Introduction: Current Role of General Medical Oncologists in the Treatment of Soft Tissue Sarcomas (STS) (0:00) Incorporation of Novel Agents and Strategies into the Management of STS — Faculty Presentation (6:38) Incorporation of Novel Agents and Strategies into the Management of STS — Survey Questions (20:34) Evolving Treatment Paradigm for Locally Aggressive STS — Faculty Presentation (31:09) Evolving Treatment Paradigm for Locally Aggressive STS — Survey Questions (46:44) CME information and select publications

Featuring perspectives from Prof Laurence Albiges and Dr Tian Zhang, including the following topics: Introduction: Adjuvant Immunotherapy for Localized Renal Cell Carcinoma (RCC) (0:00) Metastatic Clear Cell RCC — Faculty Presentation (9:22) Metastatic Clear Cell RCC — Survey Questions (20:24) Non-Clear Cell RCC — Faculty Presentation (36:02) Non-Clear Cell RCC — Survey Questions (45:46) ASCO 2025 (50:12) CME information and select publications

Featuring perspectives from Dr Catherine C Coombs and Dr William G Wierda, including the following topics: Introduction (0:00) Selection and Sequencing of Therapy for Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) — Dr Wierda (19:25) First-Line Therapy for CLL — Dr Coombs (44:18) Novel Agents and Strategies for R/R CLL — Dr Wierda (57:27) CME information and select publications

Featuring an interview with Ms Jennifer Filipi, including the following topics: Responsibilities of an oncology nurse and perspectives on the career (0:00) Case: A woman in her late 70s with BRCA1-mutated ovarian cancer (OC) (3:50) Case: A woman in her mid 40s, a mother of 3, with advanced OC (27:23) Case: A woman in her early 70s, a social worker, with platinum-refractory OC (40:02) NCPD information and select publications

Featuring perspectives from Dr Ajay K Nooka and Dr Paul G Richardson, including the following topics: Introduction: ASCO 2025 Showstoppers (0:00) Up-Front Treatment of Multiple Myeloma (MM) — Survey Questions (5:50) Emerging Novel Therapies for Relapsed/Refractory (R/R) MM — Faculty Presentation (11:57) Emerging Novel Therapies for R/R MM — Survey Questions (26:19) Current Management of R/R MM — Faculty Presentation (38:34) Current Management of R/R MM — Survey Questions (49:20) CME information and select publications

Featuring perspectives from Prof Marina Chiara Garassino, Dr John V Heymach, Prof Solange Peters and Dr Jacob Sands, moderated by Dr Sands, including the following topics: Introduction (0:00) Role of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Tumor Mutation — Prof Peters (2:07) Targeted and Other Novel Therapeutic Strategies for Relapsed Metastatic NSCLC — Prof Garassino (26:30) Potential Role of TROP2-Targeted Antibody-Drug Conjugates in Advanced NSCLC — Dr Sands (50:19) Evolving Role of Immune Checkpoint Inhibitors in the Care of Patients with Nonmetastatic NSCLC — Dr Heymach (1:12:36) CME information and select publications

Featuring perspectives from Dr Haley Ellis, Dr Sara Lonardi and Dr Kanwal Raghav, moderated by Dr Christopher Lieu, including the following topics: Introduction (0:00) Gastroesophageal Cancers — Dr Lonardi (1:54) Biliary Tract Cancers — Dr Ellis (39:20) Colorectal Cancer — Dr Raghav (1:07:10) CME information and select publications

Featuring perspectives from Dr Jacqueline Broadway-Duren, Dr Bita Fakhri, Ms Corinne Hoffman and Dr Jeff Sharman, including the following topics: Introduction: Key Factors in the Management of Chronic Lymphocytic Leukemia (CLL) (0:00) Role of Covalent Bruton Tyrosine Kinase (BTK) Inhibitors for Newly Diagnosed CLL (12:02) Role of Time-Limited Up-Front Treatment, Including Therapy Combining BTK Inhibitors and Venetoclax, for Newly Diagnosed CLL (37:55) Role of Pirtobrutinib for Relapsed/Refractory (R/R) CLL (1:02:07) CAR (Chimeric Antigen Receptor) T-Cell Therapy for R/R CLL (1:16:48) NCPD information and select publications

Featuring perspectives from Dr Matthew D Galsky, Prof Andrea Necchi and Prof Thomas Powles, moderated by Dr Galsky, including the following topics: Introduction (0:00) Current and Future Management of Muscle-Invasive Bladder Cancer — Prof Powles (1:14) Novel Intravesical Therapies Under Evaluation for Nonmetastatic Urothelial Bladder Cancer (UBC) — Prof Necchi (24:48) Selection and Sequencing of Therapy for Metastatic UBC — Dr Galsky (44:52) CME information and select publications

Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Christopher Flowers, Dr Ann LaCasce and Dr Tycel Phillips, moderated by Dr Abramson, including the following topics: Introduction (0:00) Selection and Sequencing of Available Therapies for Diffuse Large B-Cell Lymphoma — Dr Flowers (2:24) Evolving Management Paradigm for Mantle Cell Lymphoma — Dr Phillips (31:53) Integration of Novel Therapies into the Management of Follicular Lymphoma — Dr LaCasce (54:51) Integrating Bispecific Antibodies into the Management of Non-Hodgkin Lymphoma (NHL) — Dr Brody (1:11:22) Current Role of CAR T-Cell Therapy in Various NHL Subtypes — Dr Abramson (1:37:55) CME information and select publications

Featuring perspectives from Dr Anne Chiang, Ms Elizabeth Krueger, Ms Beth Sandy and Dr Erin Schenk, including the following topics: Introduction: Overview of Bispecific Antibodies (0:00) Biology of Small-Cell Lung Cancer (SCLC) and Review of Its Initial Management (13:37) Case: 63-year-old man — Ms Krueger (23:36) Current Role of Tarlatamab in Therapy for SCLC (33:40) Case: 70-year-old woman — Ms Sandy (43:41) Future Directions in the Management of SCLC (50:45) Case: 81-year-old man — Ms Krueger (1:01:24) Unique Considerations in SCLC Management (1:09:29) Case: 67-year-old woman — Ms Sandy (1:22:53) NCPD information and select publications

Featuring perspectives from Dr Christopher Flowers, Dr Manali Kamdar, Ms Robin Klebig and Ms Caitlin Murphy, including the following topics: Introduction: Overview of Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma (0:00) Current and Future Use of Bruton Tyrosine Kinase Inhibitors for Mantle Cell Lymphoma (16:09) First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) (40:03) Role of Loncastuximab Tesirine for Patients with Relapsed/Refractory (R/R) DLBCL (57:31) Role of Tafasitamab for Patients with R/R DLBCL and Follicular Lymphoma (1:16:59) NCPD information and select publications

Featuring perspectives from Dr Harold J Burstein, Dr Javier Cortés, Prof Rebecca A Dent, Dr Kevin Kalinsky, Dr Hope S Rugo and Dr Joyce O'Shaughnessy, moderated by Dr Rugo, including the following topics: Introduction (0:00) Optimizing the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Dr Cortés (3:52) Individualized Selection of Up-Front Therapy for Patients with HR-Positive, HER2-Negative mBC — Dr Kalinsky (23:10) Available Therapies for Patients with HR-Positive, HER2-Negative Disease Progressing on CDK4/6 Inhibition — Dr Burstein (48:09) Current and Potential Future Role of HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Disease — Dr O'Shaughnessy (1:04:00) Current and Future Strategies for Patients with Endocrine-Refractory HR-Positive mBC — Dr Rugo (1:22:28) Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer — Prof Dent (1:42:51) CME information and select publications

Featuring perspectives from Dr Andrea Cercek, Dr Arvind Dasari, Dr J Randolph Hecht, Dr Pashtoon Kasi and Prof Eric Van Cutsem, moderated by Dr Hecht, including the following topics: Introduction (0:00) Role of Circulating Tumor DNA (ctDNA) Evaluation in Nonmetastatic Colorectal Cancer (CRC) — Dr Dasari (2:20) Role of Immune Checkpoint Inhibitors in the Management of Nonmetastatic Microsatellite Instability-High (MSI-H) CRC — Dr Cercek (28:32) Management of Oligometastatic Disease and Hepatic-Only Metastases in CRC; Role of ctDNA Evaluation in Metastatic Disease — Dr Kasi (54:07) Role of Immune Checkpoint Inhibitors in the Management of MSI-H Metastatic CRC (mCRC) — Dr Hecht (1:14:34) Identification and Care of Patients with mCRC and Actionable Genomic Alterations — Prof Van Cutsem (1:38:17) CME information and select publications

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley, Dr Ritu Salani, Dr Alessandro D Santin and Dr Shannon N Westin, moderated by Dr Westin, including the following topics: Introduction (0:00) Up-Front Treatment for Advanced Ovarian Cancer (OC) — Dr Liu (2:00) Current Management of Relapsed/Refractory (R/R) OC; Promising Novel Agents and Strategies Under Investigation — Dr O'Malley (27:23) Role of HER2-Targeted Therapy in Advanced OC, Endometrial Cancer (EC) and Other Gynecologic Cancers — Dr Santin (50:22) First-Line Therapy for Advanced EC — Dr Westin (1:15:00) Current Therapeutic Options for R/R EC; Novel Investigational Strategies for Newly Diagnosed and Recurrent Disease — Dr Salani (1:36:45) CME information and select publications  

Featuring perspectives from Ms Ilene Galinsky, Dr Michael J Mauro, Dr Neil P Shah and Dr Sara M Tinsley-Vance, including the following topics: Introduction: Chronic Myeloid Leukemia (CML) as a Model for Targeted Treatment (0:00) Biology of CML; Role of First- and Second-Generation Tyrosine Kinase Inhibitors (TKIs) as Initial Treatment for Chronic-Phase (CP) CML (12:37) Role of Asciminib for Newly Diagnosed CP-CML (47:46) Feasibility of TKI Discontinuation for Patients with Sustained Response to Treatment (1:14:06) Management of CP-CML After Failure of Initial Therapy (1:23:04) NCPD information and select publications

Featuring perspectives from Dr Neeraj Agarwal, Dr Andrew J Armstrong, Dr Himisha Beltran, Dr Rana R McKay and Dr Fred Saad, moderated by Dr McKay, including the following topics: Introduction (0:00) Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Saad (2:12) Current Treatment for Metastatic HSPC — Dr Armstrong (26:12) Role of PARP Inhibition in Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Agarwal (49:31) Current and Future Use of Radiopharmaceuticals for mCRPC — Dr McKay (1:12:51) Promising Novel Agents and Strategies Under Investigation for the Management of Prostate Cancer — Dr Beltran (1:36:11) CME information and select publications

Featuring an interview with Dr Patrick Y Wen, including the following topics: Glioma classification (0:00) Efficacy and safety of vorasidenib in the management of IDH-mutant gliomas (4:50) Case: A woman in her early 30s with a Grade 2 astrocytoma and an IDH R132H mutation and residual disease postoperatively (11:55) Case: A man in his early 40s experiencing stable disease with vorasidenib after subtotal resection (21:46) Ongoing trial investigating vorasidenib in IDH-mutant gliomas (27:30) Current and emergent strategies for the management of glioblastoma (31:27) Optimizing patient care and quality of life (46:24) CME information and select publications

Featuring a slide presentation and related discussion from Dr Patrick Y Wen, including the following topics: Classification and pathologic diagnosis of gliomas (0:00) Role of IDH inhibitors in the management of low-grade gliomas (6:37) Ongoing trials and remaining questions in the management of IDH-mutant gliomas (19:53) CME information and select publications

Featuring perspectives from Prof Nicolas Girard, Dr Jonathan Goldman, Dr Pasi A Jänne, Dr Suresh S Ramalingam, Dr Joshua K Sabari and Dr Helena Yu, moderated by Dr Yu, including the following topics: Introduction (0:00) Evolving First-Line Treatment for Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) — Dr Yu (1:47) EGFR-Targeted Approaches for Relapsed EGFR-Mutant NSCLC; Strategies to Facilitate Delivery of Recently Approved Agents — Dr Sabari (23:48) Potential Utility of TROP2-Targeted Therapy in the Management of EGFR-Mutant NSCLC — Dr Ramalingam (45:16) Contemporary Care for Patients with Nonmetastatic EGFR-Mutant NSCLC — Dr Goldman (1:03:56) Current and Future Management of EGFR Exon 20 Mutation-Positive NSCLC — Prof Girard (1:24:40) Emerging Role of HER3-Targeted Therapy in the Management of EGFR-Mutant NSCLC — Dr Jänne (1:43:46) CME information and select publications

Featuring perspectives from Dr Geoffrey Y Ku and Dr Zev Wainberg, including the following topics: Introduction: ASCO Preview (0:00) HER2-Positive Gastroesophageal Cancers (19:03) Immunotherapy in HER2-Negative Advanced Gastroesophageal Cancers (36:11) Immunotherapy in Microsatellite Instability-High Gastroesophageal Cancers (44:04) CLDN18.2-Positive Advanced Gastroesophageal Cancers (51:30) CME information and select publications

Featuring perspectives from Prof Meletios-Athanasios (Thanos) C Dimopoulos and Dr Robert Z Orlowski, including the following topics: Introduction: ASCO 2025 Preview (0:00) Anti-CD38 Antibodies (10:12) Belantamab Mafodotin (29:45) CAR T-Cell Therapy (40:57) Bispecific Antibodies (47:33) Other Novel Agents (56:46) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Multiple Myeloma | Faculty Presentation 2: Chimeric Antigen Receptor (CAR) T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) — Meletios-Athanasios (Thanos) C Dimopoulos, MD CME information and select publications  

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Multiple Myeloma | Faculty Presentation 1: Current and Emerging Therapeutic Approaches for Multiple Myeloma (MM) — Robert Z Orlowski, MD, PhD CME information and select publications

Featuring perspectives from Dr Virginia F Borges, Ms Jamie Carroll, Mr Ronald Stein and Dr Seth Wander, including the following topics: Introduction (0:00) Role of CDK4/6 Inhibitors in Localized and Metastatic Hormone Receptor (HR)-Positive Breast Cancer (12:49) PI3K Inhibition as First-Line Treatment for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) (38:24) Clinical Utility of AKT and PI3K Inhibitors in Progressive HR-Positive mBC (1:01:44) Current and Future Role of Oral Selective Estrogen Receptor Degraders in HR-Positive mBC (1:24:38) NCPD information and select publications

Featuring perspectives from Prof Claire Harrison and Dr John Mascarenhas, including the following topics: Introduction (0:00) New Biology of Myelofibrosis (1:55) Novel Regulatory T-Cell Infusion Therapy (14:57) Myelofibrosis 2025: JAK Inhibitors (Ruxolitinib) (20:39) BET Inhibitors: Pelabresib (42:03) Navtemadlin (53:20) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Myelofibrosis | Faculty Presentation 2: Novel Investigational Strategies — John Mascarenhas, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Myelofibrosis | Faculty Presentation 1: Current Management of Myelofibrosis (MF) — Professor Claire Harrison CME information and select publications

Featuring perspectives from Dr Sunnie Kim, Ms Brooke Parker, Ms Michal Segal and Dr Manish Shah, including the following topics: Introduction: Clinical Presentation of Gastroesophageal Cancer (0:00) Management of Localized or Locally Advanced Gastroesophageal Cancers; Current and Future Role of Immune Checkpoint Inhibitors (21:44) Incorporation of Immunotherapeutic Strategies for HER2-Negative Metastatic Gastroesophageal Tumors (39:32) Role of Therapy Targeting CLDN18.2 in Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (1:00:50) Considerations in the Care of Patients with HER2-Positive Gastroesophageal Cancers (1:22:41) NCPD information and select publications

Featuring perspectives from Dr Jessica J Lin and Dr Joel W Neal, including the following topics: Introduction: Actionable Genomic Alterations (0:00) ALK (9:49) ROS1 (22:22) HER2 (31:00) RET (38:52) NTRK (45:30) MET (46:31) Novel Targeted Strategies (49:09) BRAF (54:19) KRAS G12C (55:38) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Faculty Presentation 2: Therapeutic Approaches Targeting HER2, MET, BRAF and KRAS G12C — Joel W Neal, MD, PhD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Faculty Presentation 1: Therapeutic Approaches Targeting ALK, ROS1, RET, TRK and NRG1 — Jessica J Lin, MD CME information and select publications

Featuring perspectives from Ms Kathryn M Lyle, Dr Ritu Salani, Ms Jaclyn Shaver and Dr Brian M Slomovitz, including the following topics: Introduction: Overview of Endometrial Cancer (0:00) First-Line Therapy for Advanced or Recurrent Endometrial Cancer (11:01) Role of Lenvatinib/Pembrolizumab in the Management of Progressive Advanced Endometrial Cancer (39:09) Novel Investigational Strategies for Newly Diagnosed Advanced Endometrial Cancer (1:00:15) Incidence and Management of HER2-Positive Endometrial Cancer (1:17:52) NCPD information and select publications  

Featuring perspectives from Dr Stephen M Ansell and Dr Brian T Hill, including the following topics: Introduction: Bispecific Antibodies in Community Practice (0:00) Diffuse Large B-Cell Lymphoma (7:06) CD19, CD20 or Both? AZD0486 Bispecific Antibody (29:15) Mantle Cell Lymphoma (32:36) Follicular Lymphoma (48:08) CAR T-Cell Therapy for Marginal Zone Lymphoma (57:17) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Non-Hodgkin Lymphoma | Faculty Presentation 2: Other Available and Emerging Novel Therapies for NHL — Stephen M Ansell, MD, PhD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Non-Hodgkin Lymphoma | Faculty Presentation 1: Current Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy and Bispecific Antibodies in Various Non-Hodgkin Lymphoma (NHL) Subtypes — Brian T Hill, MD, PhD CME information and select publications

Featuring perspectives from Dr Ian E Krop and Dr Sara M Tolaney, including the following topics: Introduction: Adjuvant CDK4/6 Inhibition (0:00) HER2-Positive Disease (11:13) PARP Inhibition (27:34) Antibody-Drug Conjugates (34:12) Up-Front Treatment of HR-Positive Metastatic Disease (46:28) CME information and select publications

Featuring perspectives from Dr Daniel George, Dr Leonard G Gomella and Dr Evan Y Yu, moderated by Dr George, including the following topics: Introduction (0:00) Current Treatment Landscape for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) — Dr Gomella (3:42) Clinical Implications of and Appropriate Strategies to Identify PTEN Deficiency in Prostate Cancer — Dr Yu (35:37) Emerging Role of AKT Inhibition for mHSPC — Dr George (1:06:18) CME information and select publications

Featuring perspectives from Dr Prithviraj Bose and Dr Andrew T Kuykendall, including the following topics: Systemic Mastocytosis — Dr Bose (0:00) Myelofibrosis — Dr Kuykendall (24:46) CME information and select publications

Featuring perspectives from Dr Thomas A Abrams and Dr Ahmed Omar Kaseb, including the following topics: Current Treatment for Advanced Hepatocellular Carcinoma (HCC) — Dr Abrams (0:00) Promising Novel Approaches to HCC Management — Dr Kaseb (33:46) CME information and select publications